Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Abstract 1735: The discovery of PKMYT1 inhibitors to exploit synthetic lethality caused by replication stress

Richard M. Marais, Joanna Grabarek, Myria Ioannou, Leo Leung, Ali Raoof, Mike Brown, Deborah Smithen, Chris Fitzpatrick, Chris Chester, Jacob Leigh, Mohammed Aljarah, Monika Lisauskaite, Oleksandr Grytsai, Ryan Burgin, Dan Niculescu-Duvaz, Graeme Thomson, Caroline Springer

Cancer Res (2025) 85 (8_Supplement_1): 1735.

https://doi.org/10.1158/1538-7445.AM2025-1735

Published: 21 April 2025

View articletitled, Abstract 1735: The discovery of PKMYT1 inhibitors to exploit synthetic lethality caused by replication stress

Journal Articles

Abstract LB-212: Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models

Grazia Saturno, Filipa Lopes, Maria Romina Girotti, Ion Niculescu-Duvaz, Dan Niculescu-Duvaz, Alfonso Zambon, Lawrence Davies, Louise Johnson, Natasha Preece, Amaya Viros, Malin Pedersen, Robert McLeary, Ruth Knight, Rebecca Lee, Denys Holovanchuk, Paul Lorigan, Nathalie Dhomen, Richard Marais, Caroline Springer

Cancer Res (2016) 76 (14_Supplement): LB-212.

https://doi.org/10.1158/1538-7445.AM2016-LB-212

Published: 15 July 2016

View articletitled, Abstract LB-212: Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models

Journal Articles

Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations

Cancer Res (2014) 74 (19_Supplement): 3704.

https://doi.org/10.1158/1538-7445.AM2014-3704

Published: 01 October 2014

View articletitled, Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations

Journal Articles

Abstract 4307: Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis.

Berta Sanchez-Laorden, Amaya Viros, Maria Romina Girotti, Matthew Martin, Malin Pedersen, Alfonso Zambon, Dan Niculescu-Duvaz, Caroline Springer, Richard Marais

Cancer Res (2013) 73 (8_Supplement): 4307.

https://doi.org/10.1158/1538-7445.AM2013-4307

Published: 15 April 2013

View articletitled, Abstract 4307: Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis.

Journal Articles

Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Maria R. Girotti, Malin Pedersen, Berta Sanchez-Laorden, Amaya Viros, Samra Turajlic, Dan Niculescu-Duvaz, Alfonso Zambon, John Sinclair, Andrew Hayes, Martin Gore, Caroline Springer, James Larkin, Claus Jorgensen, Richard Marais

Cancer Res (2013) 73 (8_Supplement): 3404.

https://doi.org/10.1158/1538-7445.AM2013-3404

Published: 15 April 2013

View articletitled, Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Journal Articles

The effect of gatekeeper residue mutations on the sensitivity of oncogenic BRAF to the multikinase inhibitor sorafenib.

Steven Whittaker, Ruth Kirk, Annette Affolter, Dan Niculescu-Duvaz, Caroline Springer, Richard Marais

Cancer Res (2008) 68 (9_Supplement): 4763.

Published: 01 May 2008

View articletitled, The effect of gatekeeper residue mutations on the sensitivity of oncogenic BRAF to the multikinase inhibitor sorafenib.

Journal Articles

^V599EB-RAF is an Oncogene in Melanocytes

Claudia Wellbrock, Lesley Ogilvie, Douglas Hedley, Maria Karasarides, Jan Martin, Dan Niculescu-Duvaz, Caroline J. Springer, Richard Marais

Cancer Res (2004) 64 (7): 2338–2342.

https://doi.org/10.1158/0008-5472.CAN-03-3433

Published: 01 April 2004

View articletitled, V599EB-RAF is an Oncogene in Melanocytes

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 1735: The discovery of PKMYT1 inhibitors to exploit synthetic lethality caused by replication stress

Abstract LB-212: Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models

Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations

Abstract 4307: Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis.

Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

The effect of gatekeeper residue mutations on the sensitivity of oncogenic BRAF to the multikinase inhibitor sorafenib.

^V599EB-RAF is an Oncogene in Melanocytes

Email alerts

AACR Journals

Update search

Abstract 1735: The discovery of PKMYT1 inhibitors to exploit synthetic lethality caused by replication stress

Abstract LB-212: Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models

Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations

Abstract 4307: Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis.

Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

The effect of gatekeeper residue mutations on the sensitivity of oncogenic BRAF to the multikinase inhibitor sorafenib.

V599EB-RAF is an Oncogene in Melanocytes

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

^V599EB-RAF is an Oncogene in Melanocytes